Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Liabilities and Shareholders Equity data on record, last reported at $577.4 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 63.01% year-over-year to $577.4 million; the TTM value through Sep 2025 reached $1.6 billion, up 26.54%, while the annual FY2024 figure was $374.0 million, 108.47% up from the prior year.
  • Liabilities and Shareholders Equity reached $577.4 million in Q3 2025 per DNTH's latest filing, up from $326.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $577.4 million in Q3 2025 and bottomed at $78.6 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 4 years is $258.8 million, with a median of $194.4 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 57.07% in 2023, then soared 369.19% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $83.1 million in 2022, then surged by 115.86% to $179.4 million in 2023, then skyrocketed by 108.47% to $374.0 million in 2024, then skyrocketed by 54.39% to $577.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $577.4 million in Q3 2025, $326.1 million in Q2 2025, and $348.6 million in Q1 2025.